Global Pulmonary Arterial Hypertension Market - 2023-2030

Market Overview

The Global Pulmonary Arterial Hypertension Market size was worth US$ 7 billion in 2022 and is estimated to reach US$ 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2023-2030. Although pulmonary hypertension cannot be cured, medication may reduce symptoms and assist patients in managing the condition.

Pulmonary hypertension often worsens over time. If left untreated, it can lead to cardiac failure, which can be deadly. Thus, treatment should begin as soon as possible. If pulmonary hypertension is caused by another ailment, the underlying condition should be addressed first. This can occasionally avoid lasting damage to the pulmonary arteries.

Market Dynamics

Increased rate of disease of in Geriatric patients

Increased rate of disease in Geriatric patients is one the driver that increases the market growth of the pulmonary arterial hypertension market. For instance, a recent study found that statistics from the United States and Europe show that pulmonary arterial hypertension is increasingly being detected in older individuals, who commonly have other cardiovascular comorbidities. During the study, it was discovered that the median age at the time of diagnosis of pulmonary arterial hypertension was 60 years, and 29% of the patients were 70 years or older.

High cost of treatment of Pulmonary arterial hypertension

High cost of treatment of Pulmonary arterial hypertension is one of the markets hinder which stops the Pulmonary arterial hypertension market for instance, According to studies, individuals with PAH have large pharmacy expenses due to excessive medication use.1 To complicate matters, PAH is frequently treated using injected medications that might be billed under the medical benefit with minimal visibility to cost.

Combination therapy for PAH is fairly common: 46 percent of PAH patients are on dual therapy regimens, and 9 percent are on triple therapy regimens, potentially raising payor expenses.2 TRITON, a crucial trial on double and triple therapy, exhibited significant reductions in pulmonary vascular resistance (PVR) relative to baseline, outperforming previous progressive therapy escalation.3,4 These people are enjoying longer lives and avoiding the need for lung transplants.

COVID-19 Impact Analysis

Covid possesses the main responsible mechanisms for Pulmonary Arterial Hypertension associated with COVID-19 are considered extensive pulmonary damage (due to interstitial and alveolar inflammation) as in PAH of group 3 and alterations in pulmonary vasculature (induced by thrombotic/thromboembolic processes, endothelial injury, or, at the very least, hypoxic vasoconstriction) as in PAH of group 4, but in some cases, an additional factor could be the consequences of positive end-Ex expiratory pressure used in mechanical ventilation.

Segment Analysis

The market for next-generation contact lenses and visual prostheses is segmented by drug class, route of administration, and distribution channel on a global scale.

The Oral Route Of the Administration Segment will be Dominated By Market Players During the Forecast Period.

The Oral route segment, with a percentage of around 44.3%, is dominated by market players' products during the forecast period as it is the most prevalent form of drug administration. It is the preferred method because to its advantages, such as non-invasiveness, patient compliance, and convenience of medicine administration. Medication solubility, mucosal transparency, and the stability of the digestive system environment are all variables that impact oral medication absorption.

Because inhaled drugs specifically target the receptor, they can be supplied at a lower dose than systemic therapies (oral or injectable), resulting in less mild adverse effects. Regarding clinical efficacy, the three types of aerosol devices (MDI, DPI, and nebulizer) may be comparable. As a result, the market for inhalational administration is likely to be the fastest-growing sector.

Geographical Analysis

North America is the dominating region during the forecast period.

North America is estimated to hold around 39.1% of the total market share throughout the forecast period in terms of revenue share. The sophisticated healthcare system in the region, which offers access to innovative therapies, is responsible for a large portion of this. Increased awareness, a high incidence of diagnosis, and favorable government policies contribute to market development.

In North America, pulmonary hypertension is normally diagnosed and managed by specialized healthcare experts such as pulmonologists, cardiologists, and PH specialists. They collaborate with patients to create personalized treatment programs that may include medicines, lifestyle changes, and, in certain situations, sophisticated treatments, including pulmonary arterial hypertension (PAH)-targeted pharmaceuticals, prostacyclin analogs, or lung transplantation.

Competitive Landscape

The major global players include: Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation

• Why Purchase the Report?
• To visualize the Global Pulmonary Arterial Hypertension Market segmentation based on the drug class, Route of administration and Distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous Global Pulmonary Arterial Hypertension Market level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Pulmonary Arterial Hypertension Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies